Scholar Rock Q2 2021 Earnings Report
Key Takeaways
Scholar Rock reported a net loss of $30.7 million, or $0.84 per share, and revenue of $4.6 million for the quarter ended June 30, 2021. The company's cash and cash equivalents totaled approximately $282 million at the end of the quarter.
Phase 3 trial to evaluate apitegromab in patients with non-ambulatory Type 2 and Type 3 spinal muscular atrophy (SMA) anticipated to initiate by end of 2021.
DRAGON Phase 1 trial evaluating SRK-181’s ability to overcome resistance to checkpoint inhibitors continues to progress and on-track to advance to Part B dose expansion mid-year 2021
Positive top-line data from the TOPAZ Phase 2 trial were presented, showing meaningful motor function improvements with apitegromab in SMA patients.
The FDA granted Fast Track designation for apitegromab for the treatment of patients with Spinal Muscular Atrophy.
Scholar Rock
Scholar Rock
Forward Guidance
Scholar Rock is working closely with regulatory authorities to finalize the design of the Phase 3 trial for apitegromab and to progress the DRAGON trial to Part B to evaluate SRK-181 across multiple tumor types.